Drug intelligence / Profile preview

fluorescein isothiocyanate-labeled IgG

Development stage: Preclinical
Lead developer: Counterpoint Biomedica
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

Fluorescein isothiocyanate-labeled IgG is a fluorescently tagged immunoglobulin G (IgG) molecule used primarily as a diagnostic tracer and research tool in preclinical studies. The molecule consists of an IgG antibody chemically conjugated to the fluorophore fluorescein isothiocyanate (FITC), which allows for the visualization of antibody localization and distribution via fluorescence imaging. In the context of cancer research, it has been utilized to evaluate the efficacy of tumor-targeting delivery systems, such as mAb-Tropins, by serving as a fluorescent cargo that can be tracked as it is compartmentalized within the tumor microenvironment (TME).

Other names: FITC-labeled IgGfluorescein-labeled IgG

Beyond the preview

Go deeper on fluorescein isothiocyanate-labeled IgG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluorescein isothiocyanate-labeled IgG.

Explore the full profile